OSI Pharmaceuticals Inc. (Osip)

[Slyhunter]

Tarceva(R) Delivers Benefits Across Broad Range Of Non-Small Cell ...
Medical News Today - Jun. 1, 2008
In a global alliance comprising OSI Pharmaceuticals, Genentech and Roche, almost clinical studies are being conducted with Tarceva at earlier...
http://www.medicalnewstoday.com/articles/109387.php
New data presented at ASCO 2008 from TRUST1, the largest non-small cell lung cancer (NSCLC) Phase IV trial ever conducted, show that a broad range of NSCLC patients treated with Tarceva (erlotinib) experience clinical benefits including longer survival, better quality of life, control of disease symptoms and control of cancer progression. NSCLC is the most common and deadly form of lung cancer suffered by over one million people worldwide2.